Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 13/20 | 0.58 |
| ▸ | NTSR1 | P30989 | 13/20 | 0.58 |
| ▸ | SORT1 | Q99523 | 13/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | REN | P00797 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30249014 | 0.94 | SLC6A2 (0.62) | NTSR2NTSR1SORT1SLC6A2REN | |
| SCHEMBL30446531 | 0.93 | NTSR2 (0.55) | NTSR2NTSR1SORT1SLC6A2REN | |
| SCHEMBL30248936 | 0.92 | SLC6A2 (0.53) | NTSR2NTSR1SORT1SLC6A2 | |
| SCHEMBL29737387 | 0.91 | SLC6A2 (0.62) | NTSR2NTSR1SORT1SLC6A2REN | |
| SCHEMBL30249075 | 0.89 | NTSR2 (0.57) | NTSR2NTSR1SORT1SLC6A2REN | |
| SCHEMBL30248974 | 0.88 | SLC6A2 (0.66) | NTSR2NTSR1SORT1SLC6A2 | |
| SCHEMBL30957418 | 0.88 | SLC6A2 (0.62) | SLC6A2 | |
| SCHEMBL30248935 | 0.88 | REN (0.52) | NTSR2NTSR1SORT1SLC6A2REN | |
| SCHEMBL30478148 | 0.88 | SLC6A2 (0.59) | NTSR2NTSR1SORT1SLC6A2 | |
| SCHEMBL30249139 | 0.88 | NTSR2 (0.61) | NTSR2NTSR1SORT1SLC6A2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174582-A1 | VIPR2 ANTAGONIST PEPTIDE | ICHIMARU PHARCOS CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| EP-4137502-A1 | VIPR2 ANTAGONIST PEPTIDE | Ichimaru Pharcos Co., Ltd. (JP) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174582-A1 | VIPR2 ANTAGONIST PEPTIDE | VIPR2, NPY2R, NPY5R | NTSR2 64/4885NTSR1 170/4885SORT1 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.